SYDNEY, Australia, April 13, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (Nasdaq: KZIA), a clinical-stage oncology company advancing therapies to reprogram cancer biology and overcome treatment resistance, announces the in-licensing of a first-in-class SETDB1-targeted epigenetic drug...
Hence then, the article about kazia therapeutics expands oncology platform with first in class setdb1 inhibitor drug development platform was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform )
Also on site :
- JCPenney’s ‘Delicate’ Pink Sapphire Pendant Necklace Is a ‘Beautiful’ Holiday Gift, Now 79% Off
- Southeast Asia shouldn’t copy the U.S. healthcare model, says Walgreens Boots Alliance’s APAC head: ‘It saves your life, but it’s not very healthy’
- Taiwan Audience Study Highlights Cross-Platform IP Opportunities as AI Raises New Risks for Content Industry